newest glp-1 drug Novo's Wegovy becomes first approved for MASH What are GLP-1 medications and

References Bartke A, Brannan S, Hascup E, Hascup K, Darcy J

When examining a composite cardio outcomes endpoint (death from CV disease, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina), the ELIXA trial suggested that GLP-1s did not increase cardiovascular event risk (hazard ratio of 1.02)

All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice

Finally, we computed subgroup control analyses based on the absence or presence of co-occurring diagnoses (Related-Samples Wilcoxon Signed Rank Test within-subjects before vs